Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study

What Was Tested

The paper reports a study of Somatostatin and Lanreotide, published as a randomized controlled trial.

During this trial, the researchers witnessed several episodes of hepatic cyst infection, all during lanreotide treatment.

The researchers describe these events and provide a review of the literature.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, open-label and multicenter.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label Somatostatin study: the participants and staff both knew the treatment.

More than one site took part, so the participants came from several places.

The DIPAK-1 Study is an ongoing investigator-driven, randomized, controlled, open-label multicenter trial.

Hepatic cyst infection was diagnosed by local physicians.

What Was Measured

Topics PubMed links to this paper include Cysts, Glomerular Filtration Rate, Liver Diseases, Peptides, Cyclic, Polycystic Kidney, Autosomal Dominant and Somatostatin.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Somatostatin and Lanreotide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Drug safety), a journal based in New Zealand.

More context: the Somatostatin compound page and the Lanreotide compound page.